2496 Wuhan YZY Biopharma Co., Ltd. HKEX · China

Wuhan YZY Biopharma Co. (2496) news

Wuhan YZY Biopharma Co., Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2496, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Wuhan YZY Biopharma Co. news

We have not published a story on Wuhan YZY Biopharma Co. yet. When there is news, it will appear here.

Questions about Wuhan YZY Biopharma Co.

What is the ticker symbol of Wuhan YZY Biopharma Co.?

Wuhan YZY Biopharma Co., Ltd. trades under the ticker 2496 on HKEX.

Where is Wuhan YZY Biopharma Co. listed?

Wuhan YZY Biopharma Co., Ltd. is listed on HKEX.

Which country or territory is Wuhan YZY Biopharma Co. listed under?

Our directory records Wuhan YZY Biopharma Co., Ltd. under China.

What does Wuhan YZY Biopharma Co. do?

Our directory classifies Wuhan YZY Biopharma Co., Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Wuhan YZY Biopharma Co.?

The ISIN recorded for Wuhan YZY Biopharma Co., Ltd. is CNE1000063C4.

Does aibio.space cover Wuhan YZY Biopharma Co.?

aibio.space lists Wuhan YZY Biopharma Co., Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Wuhan YZY Biopharma Co.?

Companies in our directory listed in the same country and business area as Wuhan YZY Biopharma Co.: InnoCare Pharma, Northeast Pharmaceutical Group Co., KPC Pharmaceuticals, Beijing Centergate Technologies (Holding) Co., Chimin Health Management Co., Abbisko Cayman.

Investor discussion: Wuhan YZY Biopharma Co.

Members talk about Wuhan YZY Biopharma Co. (2496). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Wuhan YZY Biopharma Co., newest first. Each line links the filing it comes from.

Sep 30, 2026Mergers
Transaction under the Listing Rules: DELAY IN DESPATCH OF CIRCULAR IN RELATION TO (1) CONNECTED TRANSACTION IN RESPECT OF THE PROPOSED ISSUE OF NEW DOMESTIC SHARES UNDER SPECIFIC MANDATE; (2) APPLICATION FOR WHITEWASH WAIVER; AND (3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION. Source
Sep 10, 2026Listings
Trading status: EXCHANGE NOTICE - RESUMPTION OF TRADING. Source
Sep 9, 2026Listings
Trading status: ANNOUNCEMENT (1) CONNECTED TRANSACTION IN RESPECT OF THE PROPOSED ISSUE OF NEW DOMESTIC SHARES UNDER SPECIFIC MANDATE; (2) APPLICATION FOR WHITEWASH WAIVER; (3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (4) APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER; AND (5) RESUMPTION OF TRADING. Source
Aug 31, 2026Listings
Trading status: TRADING HALT. Source
Aug 31, 2026Listings
Trading status: EXCHANGE NOTICE - TRADING HALT. Source
Jun 8, 2026Financings
Share or debt issue: (1) ANNUAL REPORT FOR 2025 (2) REPORT OF THE BOARD OF DIRECTORS FOR 2025 (3) REPORT OF THE SUPERVISORY COMMITTEE FOR 2025 (4) FINANCIAL REPORT FOR 2025 (5) PROFIT DISTRIBUTION PLAN FOR 2025 (6) PROPOSED REAPPOINTMENT OF THE AUDITOR FOR 2026 (7) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES AND (8) NOTICE OF THE ANNUAL GENERAL MEETING. Source
Feb 5, 2026Mergers
Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION TRANSFER OF LAND USE RIGHT AND BUILDING. Source
Jan 23, 2026Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION TRANSFER OF LAND USE RIGHT AND BUILDING. Source

Press releases

Headlines of Wuhan YZY Biopharma Co.'s own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 16, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT THE FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF Y225 FOR TREATMENT OF HEMOPHILIA A
Sep 30, 2026HKEXnews
DELAY IN DESPATCH OF CIRCULAR IN RELATION TO (1) CONNECTED TRANSACTION IN RESPECT OF THE PROPOSED ISSUE OF NEW DOMESTIC SHARES UNDER SPECIFIC MANDATE; (2) APPLICATION FOR WHITEWASH WAIVER; AND (3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Sep 30, 2026HKEXnews
UPDATE ON THE QUALIFICATION OF JOINT COMPANY SECRETARY AND RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF PROCESS AGENT
Sep 10, 2026HKEXnews
EXCHANGE NOTICE - RESUMPTION OF TRADING
Sep 9, 2026HKEXnews
ANNOUNCEMENT (1) CONNECTED TRANSACTION IN RESPECT OF THE PROPOSED ISSUE OF NEW DOMESTIC SHARES UNDER SPECIFIC MANDATE; (2) APPLICATION FOR WHITEWASH WAIVER; (3) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION; (4) APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER; AND (5) RESUMPTION OF TRADING
Aug 31, 2026HKEXnews
TRADING HALT
Aug 31, 2026HKEXnews
EXCHANGE NOTICE - TRADING HALT
Aug 28, 2026HKEXnews
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026
Jun 29, 2026HKEXnews
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MONDAY, JUNE 29, 2026
Jun 8, 2026HKEXnews
NOTICE OF THE ANNUAL GENERAL MEETING
Jun 8, 2026HKEXnews
(1) ANNUAL REPORT FOR 2025 (2) REPORT OF THE BOARD OF DIRECTORS FOR 2025 (3) REPORT OF THE SUPERVISORY COMMITTEE FOR 2025 (4) FINANCIAL REPORT FOR 2025 (5) PROFIT DISTRIBUTION PLAN FOR 2025 (6) PROPOSED REAPPOINTMENT OF THE AUDITOR FOR 2026 (7) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES AND (8) NOTICE OF THE ANNUAL GENERAL MEETING
May 22, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT DATA FROM TWO CLINICAL STUDIES OF M701 "CD3/EpCAM BISPECIFIC ANTIBODY" TO BE PRESENTED AT 2026 ASCO ANNUAL MEETING
May 15, 2026HKEXnews
CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR
May 7, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT NDA FOR TREATMENT OF MA OF M701 WAS ACCEPTED BY THE NMPA
Apr 23, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT - TWO CLINICAL STUDY RESULTS OF M701 SELECTED FOR PRESENTATION AT THE 2026 ASCO ANNUAL MEETING
Mar 30, 2026HKEXnews
INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION
Mar 27, 2026HKEXnews
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Feb 5, 2026HKEXnews
SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION TRANSFER OF LAND USE RIGHT AND BUILDING
Feb 4, 2026HKEXnews
INSIDE INFORMATION GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION OF THE COMPANY
Feb 3, 2026HKEXnews
VOLUNTARY ANNOUNCEMENT M701 RECEIVES IND APPROVAL FROM FDA

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2496 on TradingView.

Listing details

Company: Wuhan YZY Biopharma Co., Ltd.
Ticker: 2496
Listing: HKEX
Country or territory: China
Business scope: Pharmaceuticals: Major
ISIN: CNE1000063C4
Last quote in directory: 2026-10-20
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction